Easywell Biomedicals Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	597.41	540.44	271.63	178.9	197.28
Revenue Growth (YoY)	10.54%	98.96%	51.84%	-9.32%	-26.29%
Cost of Revenue	317.11	241.04	100.91	102.58	146.85
Gross Profit	280.31	299.4	170.72	76.31	50.43
Selling, General & Admin	113.02	94.88	61.96	28.16	24.15
Research & Development	237.14	274.33	271.5	209.41	238.14
Operating Expenses	347.51	374.19	333.46	237.57	262.29
Operating Income	-67.2	-74.79	-162.74	-161.26	-211.86
Interest Expense	-22.48	-21.16	-19.26	-17.25	-16.08
Interest & Investment Income	2.94	4.94	3.42	2.18	1.18
Currency Exchange Gain (Loss)	-	2.28	7.5	7.53	-1.13
Other Non Operating Income (Expenses)	11.55	0.34	1.17	0.46	57.99
EBT Excluding Unusual Items	-75.18	-88.39	-169.91	-168.34	-169.91
Gain (Loss) on Sale of Investments	-	0.16	-	0.07	0.01
Gain (Loss) on Sale of Assets	-	0.03	-	-	0.24
Other Unusual Items	-	-0.09	-	-	-
Pretax Income	-75.18	-88.29	-169.91	-168.28	-169.66
Income Tax Expense	0.3	0.16	0.26	0.12	0.85
Earnings From Continuing Operations	-75.48	-88.44	-170.17	-168.39	-170.51
Net Income to Company	-75.48	-88.44	-170.17	-168.39	-170.51
Minority Interest in Earnings	2.34	-9.02	25.35	7.39	20.12
Net Income	-73.14	-97.47	-144.82	-161	-150.39
Net Income to Common	-73.14	-97.47	-144.82	-161	-150.39
Shares Outstanding (Basic)	124	120	114	114	106
Shares Outstanding (Diluted)	124	120	114	114	106
Shares Change (YoY)	3.15%	5.03%	0.05%	7.48%	14.08%
EPS (Basic)	-0.59	-0.81	-1.27	-1.41	-1.41
EPS (Diluted)	-0.59	-0.81	-1.27	-1.41	-1.41
Free Cash Flow	109.37	-171.53	-169.17	-60.99	-136.02
Free Cash Flow Per Share	0.88	-1.43	-1.48	-0.53	-1.28
Gross Margin	46.92%	55.40%	62.85%	42.66%	25.56%
Operating Margin	-11.25%	-13.84%	-59.91%	-90.14%	-107.39%
Profit Margin	-12.24%	-18.04%	-53.31%	-90.00%	-76.23%
Free Cash Flow Margin	18.31%	-31.74%	-62.28%	-34.09%	-68.95%
EBITDA	23.93	-22.19	-121.01	-116	-160.42
EBITDA Margin	4.00%	-4.11%	-44.55%	-64.84%	-81.32%
D&A For EBITDA	91.13	52.6	41.73	45.26	51.45
EBIT	-67.2	-74.79	-162.74	-161.26	-211.86
EBIT Margin	-11.25%	-13.84%	-59.91%	-90.14%	-107.39%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.